Fig. 2

High WWP2 expression is correlated with aggressive clinical characteristics and a poor prognosis in GC patients. A The expression levels of WWP2 in different types of tumor tissues and corresponding normal tissues analyzed based on TCGA data obtained from the TIMER (https://cistrome.shinyapps.io/timer/) database (Student’s t test, p < 0.05). B The expression of WWP2 mRNA in GC tissues and matched adjacent nontumor tissues analyzed utilizing the UALCAN (http://ualcan.path.uab.edu/index.html) database (Student’s t test, p < 0.01). C–E The association between WWP2 expression and prognosis, including overall survival (OS), time to first progression (TFP)and post progression survival (PPS), in patients with GC obtained from the KM-Plotter (http://kmplot.com/analysis/) database (log-rank test, p < 0.05). F Representative images of IHC staining of WWP2 protein in human GC tissues and adjacent nontumor tissues. G Kaplan‒Meier survival analysis of patients with higher WWP2 expression levels (n = 78) and lower WWP2 expression (n = 52) (log-rank test, p < 0.05). H Western blotting analysis was performed to detect the protein expression levels of WWP2 in 8 pairs of GC tissues and paired normal tissues. I Western blotting analysis was performed to detect the protein expression of WWP2 in GES-1 and six human GC cell lines (AGS, SGC-7901, HGC-27, BGC-823, MGC-803 and MKN-45). **p < 0.01